Yükleniyor... / Loading...
Monitoring Drug Efficacy in Patients with Alzheimer's Disease
Bu çalışma, Alzheimer hastalığı (Alzheimer's disease) olan kişilerde asetilkolinesteraz (AChE) inhibitörü tek başına veya NMDA reseptör antagonisti ile birlikte kullanıldığında ilaç etkinliğini izlemektedir. Çalışmaya, yeni tanı almış, hafif veya orta düzeyde bunaması olan 65 yaşındaki hastalar alınmaktadır. Faz uygulanmayan bir çalışma olup yürütülmekte ve halen katılımcı almaktadır.
Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.
Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.
Inclusion Criteria: * newly diagnosed with mild or moderate dementia using the Montreal Cognitive Assessment and Clinical Dementia Rating (CDR) performed by a licensed psychometrician * clinically diagnosed by an expert adult neurologist as having probable AD using the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria * treatment naive for any acetylcholinesterase inhibitors or memantine OR those who have not taken any acetylcholinesterase inhibitors or memantine in the last three months for any reasons except for adverse drug reaction * age 65 years old * residing in the National Capital Region * able to read and understand written and spoken English and Filipino Exclusion Criteria: * with structural or vascular causes of dementia other than subcortical lacunes (2 or less) as seen in plain CT scan * dementia diagnosis other than AD as determined by an expert adult neurologist * with untreated depression or related psychiatric disorders in the last 6 months * use of systemic antibotics in the previous three months prior to providing fecal specimens * use of corticosteroids, immune stimulating medications, and immunosuppressive agents within the past 2 weeks or those who regularly need them for immune-related disorders * use of proton-pump inhibitors, H2-receptor antagonists, H2-receptor antagonists, tricyclic antidepressants, narcotics, anticholinergic medications, laxatives or anti-diarrheal in the past 4 weeks * large doses of commercial probiotics consumed (greater than or equal to 108 cfu or organisms per day) * major dietary change during previous month (defined as eliminating or significantly increasing a major food group) * major GI tract surgery in the past 5 years, with the exception of cholecystectomy and appendectomy * major bowel resection at any time * active uncontrolled GI disorders or diseases, including inflammatory bowel disease, indeterminate colitis, irritable bowel syndrome, persistent infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhea of unknown etiology, recurrent Clostridium difficile infection, untreated Helicobacter pylori infection, chronic constipation